sorafenib + cisplatin

Sorafenib + cisplatin is a combination regimen of two anticancer drugs used in investigational settings for the treatment of various advanced solid tumors. Sorafenib is an oral small molecule multikinase inhibitor that targets several cell surface and intracellular kinases involved in tumor cell proliferation and angiogenesis. Cisplatin is a platinum-based cytotoxic chemotherapy agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. This combination has been studied primarily in metastatic cancers such as collecting duct carcinoma of the kidney and advanced gastric cancer, often alongside other agents like gemcitabine or docetaxel[1][2]. The rationale for combining these agents lies in their complementary mechanisms—sorafenib's targeted inhibition of signaling pathways with the broad cytotoxic effects of cisplatin.

Brand names

Nexavar (for sorafenib)Platinol (for cisplatin)

Other names

sorafenib and cisplatinNEXAVAR plus cisplatin